Your browser doesn't support javascript.
loading
Community-based COVID-19 active case finding and rapid response in the Democratic Republic of the Congo: Improving case detection and response.
Otshudiema, John Otokoye; Folefack, Gervais Léon Tengomo; Nsio, Justus M; Kakema, Cathy H; Minikulu, Luigino; Bafuana, Aimé; Kosianza, Joel B; Mfumu, Antoine K; Nkwembe, Edith; Munyeku-Bazitama, Yannick; Makiala-Mandanda, Sheila; Guinko, Noé; Mbuyi, Gisèle; Tshilumbu, Jean-Marie K; Saidi, Guy N; Umba-di-Masiala, Moreau-Serge; Ebondo, Amos K; Mutonj, Jean-Jacques; Kalombo, Serge; Kabeya, Jad; Mawanda, Taty K; Bile, Faustin N; Kasereka, Gaby K; Mbala-Kingebeni, Placide; Ahuka-Mundeke, Steve; Karamagi, Humphrey Cyprian; Fai, Karl Njuwa; Djiguimde, Amédée Prosper.
  • Otshudiema JO; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Folefack GLT; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Nsio JM; COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
  • Kakema CH; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Minikulu L; COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
  • Bafuana A; COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
  • Kosianza JB; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Mfumu AK; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Nkwembe E; COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.
  • Munyeku-Bazitama Y; COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.
  • Makiala-Mandanda S; COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.
  • Guinko N; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Mbuyi G; COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.
  • Tshilumbu JK; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Saidi GN; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Umba-di-Masiala MS; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Ebondo AK; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Mutonj JJ; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Kalombo S; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Kabeya J; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Mawanda TK; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Bile FN; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Kasereka GK; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Mbala-Kingebeni P; COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.
  • Ahuka-Mundeke S; COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.
  • Karamagi HC; Data Analytics and Knowledge Management, World Health Organization Regional Office for Africa, Brazzaville, Democratic Republic of Congo.
  • Fai KN; Research Arm - MSF Epicentre, Yaoundé, Cameroon.
  • Djiguimde AP; COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.
PLoS One ; 18(5): e0278251, 2023.
Article en En | MEDLINE | ID: mdl-37200322
A community-based coronavirus disease (COVID-19) active case-finding strategy using an antigen-detecting rapid diagnostic test (Ag-RDT) was implemented in the Democratic Republic of Congo (DRC) to enhance COVID-19 case detection. With this pilot community-based active case finding and response program that was designed as a clinical, prospective testing performance, and implementation study, we aimed to identify insights to improve community diagnosis and rapid response to COVID-19. This pilot study was modeled on the DRC's National COVID-19 Response Plan and the COVID-19 Ag-RDT screening algorithm defined by the World Health Organization (WHO), with case findings implemented in 259 health areas, 39 health zones, and 9 provinces. In each health area, a 7-member interdisciplinary field team tested the close contacts (ring strategy) and applied preventive and control measures to each confirmed case. The COVID-19 testing capacity increased from 0.3 tests per 10,000 inhabitants per week in the first wave to 0.4, 1.6, and 2.2 in the second, third, and fourth waves, respectively. From January to November 2021, this capacity increase contributed to an average of 10.5% of COVID-19 tests in the DRC, with 7,110 positive Ag-RDT results for 40,226 suspected cases and close contacts who were tested (53.6% female, median age: 37 years [interquartile range: 26.0-50.0)]. Overall, 79.7% (n = 32,071) of the participants were symptomatic and 7.6% (n = 3,073) had comorbidities. The Ag-RDT sensitivity and specificity were 55.5% and 99.0%, respectively, based on reverse transcription polymerase chain reaction analysis, and there was substantial agreement between the tests (k = 0.63). Despite its limited sensitivity, the Ag-RDT has improved COVID-19 testing capacity, enabling earlier detection, isolation, and treatment of COVID-19 cases. Our findings support the community testing of suspected cases and asymptomatic close contacts of confirmed cases to reduce disease spread and virus transmission.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País como asunto: Africa Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País como asunto: Africa Idioma: En Año: 2023 Tipo del documento: Article